Early FDG PET in Melanoma



Status:Recruiting
Conditions:Skin Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/7/2018
Start Date:March 2016
Contact:Michael Farwell, MD
Email:PennCancerTrials@emergingmed.com
Phone:855-216-0098

Use our guide to learn which trials are right for you!

Early FDG PET/CT Imaging as a Measure of Response in Patients With Melanoma on Pembrolizumab.

Adult patients with histologically proven melanoma who will be treated with pembrolizumab
will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG
uptake will be correlated with lab and pathology results.


Inclusion Criteria:

- Adult patients, at least 18 years of age

- History of histologically confirmed melanoma as assessed per medical record review.

- Eligible for the trial UPCC #01615, "A Phase Ib Tissue Collection Study of
Pembrolizumab (MK-3475) in Subjects with Resectable Advanced Melanoma."

- Participants must be informed of the investigational nature of this study and provide
written informed consent in accordance with institutional and federal guidelines prior
to study-specific procedures.

Exclusion Criteria:

- Females who are pregnant or breast-feeding at the time of screening will not be
eligible for this study. Female participants of child-bearing potential will have a
urine or serum pregnancy test at the time of the screening visit.

- Inability to tolerate imaging procedures in the opinion of the investigator or
treating physician.

- Serious or unstable medical or psychological conditions that, in the opinion of the
investigator would compromise the subject's safety or successful participation in the
study.

- Ineligible for the trial UPCC #01615, "A Phase Ib Tissue Collection Study of
Pembrolizumab (MK-3475) in Subjects with Resectable Advanced Melanoma."

- Only individuals (aged 18 or over) who can understand and give informed consent will
be eligible to participate in this study. Individuals who are considered to be
mentally disabled will not be recruited for this study. All subjects must be able to
give informed consent. We will not be using specific methods to assess decisional
capacity. Economically disadvantaged persons will not be vulnerable to undue
influence, as this study offers no compensation. All individuals will be told that
their choice regarding study participation will in no way change their access to
clinical care. This should negate any undue influence or coercion. Children, fetuses,
neonates, or prisoners are not included in this research study.
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
(215) 662-6065
Phone: 855-216-0098
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials